2024 China Biotech Out-Licensing Deal Trends Analysis
Annual Deal Overview
In 2024, Chinese biotech out-licensing deals surged to record-breaking levels. According to preliminary data, over 120 out-licensing transactions were completed throughout the year, with total deal values exceeding USD 50 billion — both figures setting new all-time highs.
In terms of deal size, the proportion of large transactions with upfront payments exceeding USD 100 million increased significantly, demonstrating strong global pharma recognition of Chinese innovative pipeline assets. Oncology remains the most active therapeutic area, but immunology and autoimmune segments showed the fastest growth in deal activity.
Leading Therapeutic Areas
ADCs (antibody-drug conjugates) continued to lead in both deal volume and value. Total ADC deal value in 2024 exceeded USD 20 billion, accounting for over 40% of the year's total. Bispecific antibodies, cell therapies, and small molecule drugs also represented significant deal categories.
Notably, licensing deals for AI-assisted drug discovery platforms have begun to emerge, with multiple transactions involving AI-driven target identification and molecular design attracting significant industry attention.
Future Outlook
Looking ahead to 2025, we expect Chinese biotech out-licensing deals to maintain strong growth momentum. As more innovative pipelines advance into late-stage clinical development and global pharma companies deepen their understanding of China's innovation capabilities, cross-border licensing transactions are likely to continue expanding in scale.
We recommend that Chinese biotech companies pursuing out-licensing focus on differentiated pipeline positioning and international clinical data standards, while selecting the right transaction partners and advisory teams to maximize pipeline value.